Ex parte EDDY - Page 8




              Appeal No. 1995-2772                                                                                      
              Application 08/001,063                                                                                    



              obvious to said person that the transformation of a host cell with said gene would result in              
              the production of a cell capable of making more biotin than a cell not transformed with said              
              gene, or would this task have been “obvious to try” by said hypothetical person.  Our                     
              appellate reviewing court distinguished these two situations in In re O’Farrell, 853 F.2d at              
              903, 7 USPQ2d at 1681 stating:                                                                            
                            The admonition that "obvious to try" is not the standard under § 103 has                    
                     been directed mainly at two kinds of error.  In some cases, what would have been                   
                     "obvious to try" would have been to vary all parameters or try each of numerous                    
                     possible choices until one possibly arrived at a successful result, where the prior art            
                     gave either no indication of which parameters were critical or no direction as to                  
                     which of many possible choices is likely to be successful.  E.g., In re Geiger, 815                
                     F.2d at 688, 2 USPQ2d at 1278; Novo Industri A/S v. Travenol Laboratories, Inc.,                   
                     677 F.2d 1202, 1208, 215 USPQ 412, 417 (7th Cir. 1982); In re Yates, 663 F.2d                      
                     1054, 1057, 211 USPQ 1149, 1151 (CCPA 1981);  In re Antonie, 559 F.2d at 621,                      
                     195 USPQ at 8-9.  In others, what was "obvious to try" was to explore a new                        
                     technology or general approach that seemed to be a promising field of                              
                     experimentation, where the prior art gave only general guidance as to the particular               
                     form of the claimed invention or how to achieve it.  In re Dow Chemical Co., 837                   
                     F.2d, 469, 473, 5 USPQ2d 1529, 1532 (Fed. Cir. 1985); Hybritech, Inc. v.                           
                     Monoclonal Antibodies, Inc., 802 F.2d 1367, 1380, 231 USPQ 81, 90-91 (Fed. Cir.                    
                     1986), cert. denied, [ ] 107 S.Ct. 1606 [ ] (1987); In re Tomlinson; 363 F.2d 928,                 
                     931, 150 USPQ 623, 626 (CCPA 1966).                                                                
                     The initial burden of establishing a prima facie case of obviousness lies with the                 
              examiner.  In re Oetiker, 977 F.2d 1443, 1445, 24 USPQ2d 1443, 1444 (Fed. Cir. 1992);                     
              In re Piasecki, 745 F.2d 1468, 1471-72, 223 USPQ 785, 787-88 (Fed. Cir. 1984).  Here,                     
              we find that the examiner has gone to great lengths to explain the teachings of the prior art,            
              and to explain why it would have been obvious to a person having ordinary skill in the art to             

                                                           8                                                            





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  Next 

Last modified: November 3, 2007